Table 4.

RCTs with pharmacological and non-pharmacological combined interventions

Intervention	Design, N. of participants	Period (week), dose	Primary measurement	Significance
Fluoxetine + graded exercise [69]	Exercise + fluoxetine: 33 Exercise + placebo: 34 Appointment + fluoxetine: 35 Appointment + placebo: 34	24 20 mg/day	Chalder scale	Graded exercise P < 0.05
Dialyzable leukocyte extract (DLE) + CBT [70]	DLE + CBT: 20 DLE + clinic: 26 Placebo + CBT: 21 Placebo + clinic: 23	28 5·10⁸ leukocytes 8 times biweekly	VAS (global well-being)	Not significant

Intervention

Design, N. of participants

Period (week), dose

Primary measurement

Significance

Fluoxetine + graded exercise [69]

Exercise + fluoxetine: 33

Exercise + placebo: 34

Appointment + fluoxetine: 35

Appointment + placebo: 34

20 mg/day

Chalder scale

Graded exercise

P < 0.05

Dialyzable leukocyte extract (DLE) + CBT [70]

DLE + CBT: 20

DLE + clinic: 26

Placebo + CBT: 21

Placebo + clinic: 23

5·10⁸ leukocytes

8 times biweekly

VAS (global well-being)

Not significant

VAS Visual Analogue Scale